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OBJECTIVES We sought to study the rate related effects of sotalol on myocardial contractility and to test
the hypothesis that the class III antiarrhythmic effect of sotalol has a reverse use-dependent
positive inotropic effect in the intact heart.
BACKGROUND Antiarrhythmic drugs exert significant negative inotropic effects. Sotalol, a beta-adrenergic
blocking agent with class III antiarrhythmic properties, may augment contractility by virtue
of its ability to prolong the action potential duration (APD).
METHODS In 10 anesthetized dogs, measurements of left ventricle (LV) peak (1)dP/dt and simultaneous
endocardial action potentials were made during baseline conditions and after sequential
administration of esmolol and sotalol. In addition, electrical and mechanical restitution curves
were constructed at a basic pacing cycle length of 600 ms by introducing a test pulse of altered
cycle length ranging from 200 ms to 2,000 ms.
RESULTS In the steady state pacing experiments, sotalol prolonged the APD in a reverse use-dependent
manner; such an effect was not seen with esmolol. At cycle lengths exceeding 400 ms, LV
(1)dP/dt was significantly higher with sotalol than it was with esmolol. There was a direct
relation between APD and LV (1)dP/dt with sotalol (r 5 0.46, p , 0.001), but there was
no significant relation between APD and LV (1)dP/dt with esmolol (r 5 0.27, p 5 NS).
Results in the single beat (restitution) studies were qualitatively similar to the steady state
results; APD (at cycle length .400 ms) and LV (1)dP/dt (at cycle length .600 ms) were
significantly higher with sotalol than they were with esmolol.
CONCLUSIONS The reverse use-dependent prolongation of APD by sotalol is associated with a positive
inotropic effect. (J Am Coll Cardiol 2000;36:1404–10) © 2000 by the American College of
Cardiology
Cardioactive agents that act through their effects on ion
channels exhibit rate dependent effects on myocardial con-
tractile function and electrophysiologic properties. Use de-
pendency whereby a progressive increase in sodium channel
blockade is seen with faster heart rates has been documented
for many of the class I antiarrhythmic agents (1,2). For
example, the slowing of conduction produced by flecainide
becomes more pronounced at faster rates. By contrast, class
III antiarrhythmic agents, such as sotalol that selectively
block the rapid component of the delayed rectifier potas-
sium channel, produce a progressive prolongation of action
potential duration (APD) at slower heart rates (3,4). Thus,
these class III agents exhibit reverse use dependency on the
action potential duration.
In addition to their electrophysiologic effects, many
antiarrhythmic agents have significant influences on myo-
cardial contractility. Most exert a negative inotropic effect
that limits their use in patients with depressed left ventric-
ular (LV) function (5,6). It has been suggested that class III
agents, by their effect of prolonging APD and, hence, the
time for calcium entry, may in fact negate or attenuate any
potential effect on ventricular contractility. For example,
sotalol, which is a beta-adrenergic receptor blocking agent
with potassium channel blocking effects, has been reported
to have less depressant effect on contractility compared with
propranolol (7,8). The rate dependent effects of sotalol on
contractility and the relationship between changes in con-
tractility and changes in APD produced by sotalol have not
been systematically explored in the intact heart.
We, therefore, designed this study to define the effects of
sotalol on the rate related changes in APD and contractility
in canine hearts and to examine the relationship between the
changes produced in APD and contractility. These effects were
investigated under steady state pacing conditions and with
single test pulses at progressively longer coupling intervals. In
order to identify the additional class III effect of sotalol and
separate this from its beta-blocker effect, the sotalol data were
compared with those obtained with esmolol. Esmolol is a
beta-1 selective blocker without intrinsic sympathomimetic or
membrane stabilizing activity and has no known electrophys-
iological effects other than via beta-blocking effects (9).
METHODS
Experimental preparation. The study protocol was ap-
proved by the Lahey Clinic Animal Research Committee
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and conforms to the position of the American Heart
Association on research animal use. Ten adult mongrel dogs
of either sex with an approximate weight of 25 kg were
premedicated with intravenous pentobarbital and intubated.
Positive pressure ventilation was maintained on an artificial
respirator. Halothane carried in a 1:1 oxygen nitrogen
mixture was used for maintenance of anesthesia. Ventilation
was controlled so as to maintain arterial pH between 7.35
and 7.4 and PCO2 between 35 and 40 mm Hg. Core
temperature was maintained between 37°C and 38°C by a
heating blanket on the operating table. The left external
jugular vein and the left carotid artery were cannulated with
8F sheaths. The chest was then opened with a left thora-
cotomy, and the heart was suspended in a pericardial cradle.
An 8F micromanometer tipped catheter (Millar Mikro-Tip,
Millar Instruments, Inc., Houston, Texas) was inserted
through an apical stab incision to record LV pressure and
the time derivative of pressure (dP/dt); LV peak (1)dP/dt
was used as an index of contractility. Pacing wires were
sutured to the right ventricular outflow tract and left atrium
appendage for bipolar pacing of these chambers.
Complete heart block was created using catheter based
radiofrequency ablation of the atrioventricular (AV) node.
Under fluoroscopy, a 7F deflectable tip catheter (EP Tech-
nologies, Inc., Sunnyvale, California) was positioned in the
right AV junction where a His bundle electrogram was
recorded (three experiments) or via a transaortic retrograde
approach in the LV septum immediately below the non-
coronary cusp (seven experiments). Radiofrequency current
in the form of a 500 kHz continuous unmodulated wave
form was delivered from a generator (Radionics, Inc.,
Burlington, Massachusetts) in a unipolar fashion to the
catheter tip. The energy output was increased to levels
between 25 and 40 W until permanent complete heart block
was achieved. The hearts were paced from the right ven-
tricular outflow tract.
Monophasic action potential (MAP) recordings and sig-
nal processing. Monophasic action potential recordings
were obtained from the endocardial surface of the heart. A
7Fr endocardial MAP catheter mounted with silver/silver
chloride electrodes (EP Technologies, Inc.) was introduced
through the sheath in the carotid artery into the LV and
positioned in a location where stable signals of amplitude
greater than 10 mV were obtained. The MAP signals were
processed using a DC-coupled isolated preamplifier (EP
Technologies, Inc.) and the output processed and amplified
in a Model 5900 Signal Conditioner (Gould Instruments,
Inc., Valley View, Ohio). The MAP and LV pressure
signals were displayed on a MAG monitor (Gould Instru-
ments, Inc.) and printed real time on a TA5000 thermal
array recorder (Gould Instruments, Inc.) at 200 mm/s paper
speed.
Recognizing that electrical or mechanical restitution may
be variably governed by diastolic interval rather than cycle
length, we plotted data (in pilot studies) using diastolic
intervals and cycle lengths; no clear differences were evident.
Therefore, we chose to display the data using cycle lengths
in order to maintain uniformity of data presentation.
Pacing protocol. The atria were paced at rapid rates (300
beats/min) to eliminate effective atrial contraction and
minimize variations in LV preload that could have resulted
from AV dissociation caused by complete heart block.
Steady state curves were constructed by pacing the right
ventricle using a constant current stimulator with 1.9 ms
pulse duration and twice diastolic current threshold at cycle
lengths of 300, 400, 600, 800, 1,000 and 1,500 ms. Each
rate was maintained for a minimum of 3 min to allow
attainment of steady states. Subsequently, electrical and
mechanical restitution curves were constructed at a basic
cycle length of 600 ms by introducing a single test pulse of
altered cycle length after each eighth steady state beat such
that the test pulse intervals spanned a range of 200 to
2,000 ms. During pacing protocols, a surface electrocardio-
gram lead, LV pressure, LV dP/dt and endocardial MAPs
were recorded.
Measurements were made during the baseline drug-free
state, after an infusion of esmolol at a rate of 150 to 250
mg/kg/min to achieve a 20% reduction of the sinus rate
(determined by examining the unpaced atrial rates) and after
sotalol (2 mg/kg) administration (10). A period of 45 to
60 min was allowed between cessation of esmolol infusion
and commencement of sotalol to permit complete elimina-
tion of esmolol.
Data analysis. Monophasic action potential recordings
with an amplitude greater than 10 mV were used for
analysis. Measurements of MAP duration were made man-
ually at 90% repolarization (APD90). Data obtained when
heart rate control was lost (for example, during spontaneous
junctional rhythms) were not employed for analysis.
Data are expressed as mean 6 SEM. Left ventricular
peak (1)dP/dt and APD at different cycle lengths were
compared utilizing two-way repeated measures analysis of
variance. Best fit linear regression analysis was performed
for the force frequency relationship and cycle length depen-
dence of APD. A Pearson product moment correlation
coefficient was obtained between changes in LV peak
(1)dP/dt and APD produced by sotalol and esmolol. A p
value of ,0.05 was considered statistically significant.
RESULTS
An example of a portion of a steady state pacing experiment
is shown in Figure 1. In the baseline state, the APD
increased from 185 to 260 ms when the pacing interval
Abbreviations and Acronyms
APD 5 action potential duration
AV 5 atrioventricular
LV 5 left ventricle or ventricular
MAP 5 monophasic action potential
dP/dt 5 time derivative of pressure
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increased from 400 to 1,000 ms; this was accompanied by a
decline in LV systolic pressure (78 to 64 mm Hg) and a
reduction in peak (1)dP/dt (770 to 525 mm Hg). After
sotalol, the action potential increased from 230 to 340 ms;
this was accompanied by smaller changes in LV systolic
pressure (94 to 88 mm Hg) and peak (1)dP/dt (945 to
805 mm Hg/s). This example illustrates the direct relation
between cycle length and APD and the effect of sotalol. The
negative inotropic effect of a long interval is attenuated by
sotalol.
Steady state pacing experiments (n 5 10). The relation
between steady state APD and cycle length is shown in the
upper panel of Figure 2. In the baseline state and with
esmolol, APD increased as a function of cycle length. After
sotalol, the APD was significantly longer than that seen
during the baseline state and after esmolol (p , 0.001); the
absolute prolongation was most marked at the longest cycle
lengths (17% at short cycle lengths vs. 23% at long cycle
lengths). This greater prolongation of APD at slower heart
rates indicates a reverse use-dependent effect of sotalol.
Figure 1. Effect of sotalol on action potential duration and left ventricular pressure transients during steady state pacing. In the baseline state, an increase
in the pacing cycle length (from 400 to 1,000 ms) produced a 40% increase in the action potential duration and a reduction in peak (1)dP/dt. After sotalol,
an increase in the pacing cycle length produced a greater (48%) increase in the action potential duration and the decline in (1)dP/dt was markedly
attenuated. dP/dt 5 time derivative of pressure; PCL 5 pacing cycle length.
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The relation between LV peak (1)dP/dt and cycle length
is shown in the lower panel of Figure 2. During the baseline
state, LV peak (1)dP/dt was maximal at a pacing cycle
length of 400 ms, and it decreased as a function of
increasing cycle length (r 5 20.43, p , 0.01). Esmolol,
while maintaining a similar inverse relation (r 5 20.39, p ,
0.01), displaced the curve downward, indicating a depres-
sant effect on contractility. Left ventricular peak (1)dP/dt
with sotalol was significantly higher than with esmolol at
cycle lengths of exceeding 400 ms; it was higher than
baseline only at the longest cycle lengths. Thus, sotalol
nearly abolished the force frequency relation, and it ap-
peared to exert a relatively positive inotropic effect at long
cycle lengths.
As shown in Figure 3, there was a positive relation
between changes in APD and peak (1)dP/dt with sotalol
(r 5 0.46, p , 0.001). By contrast, there was no significant
relation between APD and peak (1)dP/dt with esmolol
(r 5 0.27, p 5 NS). These data indicate that the preserved/
augmented contractility seen with sotalol (Fig. 2) is related
to its class III reverse use-dependent effects.
Restitution experiments. The relation between a single
test pulse (with progressive increase in coupling interval)
and APD is shown in Figure 4. After sotalol, the APD of
the premature beat (test pulse) was longer than that seen in
the baseline and esmolol states (at coupling intervals exceed-
ing 400 ms, p , 0.001). The peak (1)dP/dt was higher
than that seen with esmolol (at coupling intervals exceeding
600 ms, p , 0.01); the peak (1)dP/dt was also higher than
that seen in the baseline state, but this did not achieve
statistical significance. These data are qualitatively similar to
those in the steady state pacing studies in that APD, and
(1)dP/dt with sotalol were significantly higher than those
seen with esmolol.
DISCUSSION
The primary findings of this study are: 1) sotalol produced
an increase in the APD in a reverse use-dependent manner.
2) During steady state pacing, esmolol had a negative effect
on LV contractility, while sotalol exhibited a positive effect,
particularly at longer cycle lengths. 3) The preservation of
contractility by sotalol correlates with prolongation of the
APD. 4) The single test pulse (restitution) results were
qualitatively similar to the steady state pacing results;
relative to esmolol, sotalol produced an increase in APD and
contractility. It appears, therefore, that the depressant effect
of a beta-blocker on the relation between electromechanical
parameters and cycle length are largely reversed when the
agent has class III reverse use-dependent effects. Indeed, our
data indicate a positive inotropic effect of sotalol, which
becomes apparent at long cycle lengths.
Sotalol and steady state pacing. Sotalol, a beta-blocker
with potassium blocking properties, is known to produce
action potential and QT interval prolongation at slow rates
with little or no prolongation at rapid rates (1,3,4,11). This
effect has been demonstrated in vitro and in vivo and is
related to blockage of the rapid component of the delayed
rectifier potassium current (12). This current plays an
important role in physiologic repolarization, but its contri-
bution is reduced at rapid rates or during sympathetic
stimulation when the slow component of the current be-
comes more prominent. Thus, compounds that predomi-
nantly block the rapid component delayed rectifier (Ikr)
potassium current manifest reverse use dependency, pro-
longing APD at longer cycle lengths.
A positive inotropic effect of APD prolongation has been
suggested by a number of investigators (7,8,13,14). Aberg et
al. (7) and Hoffman et al. (8) showed that sotalol exerted
less depression of contractility compared with propranolol
in intact dog hearts. Exploring the rate related effects of
sotalol, Lathrop (12) utilized canine Purkinje strand fibers
to demonstrate that force development by sotalol was
enhanced when stimulated at slow rates. Although it was
proposed that action potential prolongation and increased
Figure 2. Action potential duration (APD90) and left ventricular peak
(1)dP/dt in steady state pacing experiments. As cycle length increased,
action potential duration progressively increased in all three states. After
sotalol, the APD was significantly longer than that seen during the baseline
state and with esmolol (*p , 0.001; p , 0.001 for interaction). Left
ventricular peak (1)dP/dt was higher with sotalol than it was with esmolol
(significant at cycle lengths above 400 ms [*p , 0.001; p , 0.001 for
interaction]); moreover, the inverse relation between peak (1)dP/dt and
cycle length (seen in baseline and esmolol states) was abolished by sotalol.
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calcium availability were the underlying mechanisms, con-
comitant organ (i.e., intact heart) electrophysiological data
are lacking. In this study, radiofrequency ablation of the AV
junction was used to allow pacing at very long cycle lengths
and permit evaluation over a wide range of heart rates, a
feature usually reserved for in vitro studies. Our studies
indicate that sotalol, by prolonging APD in a reverse
use-dependent manner, is associated with an increase in
ventricular contractility. Interestingly, this effect of the drug
appears to abolish the positive force frequency relation by
attenuating the negative inotropic effect of bradycardia.
The precise mechanism underlying a maintained contrac-
tility at slow rates is unknown. In pharmacological doses,
sotalol does not have a direct effect on the calcium channels
(15); therefore, an indirect effect must be considered. White
et al. (13) studied compound II, a class III antiarrhythmic
drug similar to sotalol but with no beta-blocking properties.
They were able to demonstrate that the drug reduced
calcium extrusion via the sodium-calcium exchange, allow-
ing augmented cellular uptake of calcium and more calcium
available for release in subsequent beats. A second potential
effect of prolonging APD is that more time would be
available for L-type calcium channels to conduct calcium;
this could provide additional “trigger calcium” and thus
augment release of calcium from the sarcoplasmic reticulum
(16). It is known that the calcium influx through the L-type
calcium channels is unable (by itself) to produce a significant
muscle twitch. Rather, it acts as a trigger for calcium release
from the sarcoplasmic reticulum, the so-called “calcium-
induced calcium release” (17).
Sotalol and restitution. Mechanical restitution is usually
characterized by a steep initial slope of the strength-interval
relation at short coupling intervals followed by a plateau at
long coupling intervals (18). This form of strength-interval
relation has been interpreted in terms of calcium ion
movements and the presence of a two compartment calcium
model (19,20). During relaxation, calcium is actively taken
up by the sarcoplasmic reticulum, stored in a temporary
compartment and eventually transferred into a labile or
release compartment. This transfer is time-dependent.
Thus, the calcium content of the labile store, which deter-
mines the inotropic state of the myocardium, is heavily
dependent on the preceding history of activity (21). During
excitation-contraction, the amount of calcium released from
the labile store is governed by the rate of rise and magnitude
of the inward calcium current.
The electrical and mechanical restitution curves shown in
Figure 4 illustrate a prolonged APD and a higher (1)dP/dt
during the plateau phase in the sotalol versus esmolol states.
Thus, a longer APD appears to provide for more calcium
availability and an increased contractility. These restitution
data are consonant with those in the steady state pacing
studies; there was approximately a 70 to 80 ms difference in
the APD and approximately a 300 to 400 mm Hg/s
difference in (1)dP/dt in the sotalol versus esmolol states.
When expressed as a percent difference, however, the
difference in max (1)dP/dt (sotalol vs. esmolol) was greater
in the steady state than it was in the single test restitution
studies (approximately 30% vs. 90%). This finding is in
keeping with the complex dependence of contractility on
previous APDs and diastolic intervals.
In clinical practice, many antiarrhythmic drugs exert
negative inotropic effects that limit their use in patients with
arrhythmia and coexistent LV dysfunction. In such patients,
prolongation of the APD may confer a protective effect on
ventricular function. For example, amiodarone, a drug with
predominant class III activity, has been shown to improve
contractility in patients with severe ventricular dysfunction
(22). Similarly, in the clinical setting, sotalol has minimal
effects on LV function, despite its beta-blocking properties
Figure 3. Relation between LV peak (1)dP/dt and action potential duration (APD90) during the steady state pacing experiments with sotalol and esmolol.
In the sotalol experiments (left panel), there was a significant direct relation between APD and LV (1)dP/dt. By contrast, no such relation was seen in
the esmolol experiments (right panel). LV 5 left ventricular.
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(23,24). In this study, we have demonstrated a reverse
use-dependent inotropic benefit of sotalol on cardiac con-
tractility, and it is possible that the clinical combination of
the APD prolongation and beta-blockade will slow the
heart rate to a range in which a protective effect on
contractility is seen. Our results offer a mechanistic expla-
nation for the potential beneficial effects of combining
beta-blockade and a class III antiarrhythmic effect.
Study limitations. It is possible that the beta-blocking
effects of esmolol and sotalol in doses used in this study were
not equivalent. Comparing sinus rates would not have
ensured equipotent beta-blockade because the class III
activity of sotalol exerts direct dromotropic effects on the
sinus node. Hence, we had to rely on standard doses of
sotalol used in previously published experimental work.
Sotalol has different concentration response curves for
beta-blockade and class III activity; beta-blockade is
achieved at lower concentrations before class III activity
becomes apparent. In doses used in this study where
significant class III activity was manifest, we expect to have
achieved levels of beta-blockade comparable to that seen
with clinical use of the drug. Study utilizing a pure class III
agent such as d-sotalol would have been of interest. This
drug is, however, not available for clinical use. Our data with
d-l sotalol maintains a degree of clinical applicability in that
slow heart rates at which inotropic effects were evident are
more likely to be achieved with a beta-blocker–class III
combination than with a pure class III agent. Secondly,
unlike sotalol, esmolol has relative cardioselectivity, and a
potential drawback is that the two drugs may not be strictly
comparable in their beta-blocking properties. Esmolol was
selected for these experiments because of its short duration
of action and because, like sotalol, it has no intrinsic
sympathomimetic activity. Finally, our recordings of action
potentials were obtained from the endocardial surface. It is
possible that recordings from the midmyocardial layers,
where APD-cycle length relationships are most pro-
nounced, may have yielded different results. However, APD
changes follow the same direction in both layers, and it is
likely that our results are representative of the global LV
repolarization characteristics.
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